Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2022-10-03 Sale | 2022-10-05 4:42 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $9.7579 | $46,155 | 125,997 (Direct) | View |
2022-09-16 Purchase | 2022-09-16 4:34 pm | Edgewise Therapeutics Inc. | EWTX | Thompson Peter A. Director 10% Owner | 484,496 | $10.32 | $4,999,999 | 14,301,551 (Indirect) | View |
2022-09-16 Purchase | 2022-09-16 4:31 pm | Edgewise Therapeutics Inc. | EWTX | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC Director 10% Owner | 484,496 | $10.32 | $4,999,999 | 14,301,551 (Indirect) | View |
2022-09-14 Purchase | 2022-09-16 2:35 pm | Edgewise Therapeutics Inc. | EWTX | Novo Holdings A/S 10% Owner | 484,496 | $10.32 | $4,999,999 | 6,071,703 (Direct) | View |
2022-09-06 Sale | 2022-09-08 4:16 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $10.91 | $51,598 | 130,727 (Direct) | View |
2022-08-03 Sale | 2022-08-05 4:12 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 9,232 | $9.3069 | $85,921 | 248,015 (Direct) | View |
2022-07-05 Sale | 2022-07-07 4:23 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 9,232 | $8.3683 | $77,256 | 395,480 (Direct) | View |
2022-06-16 Sale | 2022-06-21 6:50 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 67,927 | $6.8299 | $463,935 | 607,580 (Direct) | View |
2022-06-13 Sale | 2022-06-15 6:39 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 26,381 | $6.0823 | $160,457 | 644,324 (Direct) | View |
2022-06-08 Sale | 2022-06-10 6:34 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 27,306 | $6.441 | $175,878 | 507,463 (Direct) | View |
2022-06-03 Sale | 2022-06-07 7:03 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 47,287 | $6.2593 | $295,985 | 797,815 (Direct) | View |
2022-05-18 Purchase | 2022-05-20 4:38 pm | Edgewise Therapeutics Inc. | EWTX | ORBIMED ADVISORS LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC Director 10% Owner | 138,000 | $7.21 | $994,980 | 13,817,055 (Indirect) | View |
2022-05-18 Purchase | 2022-05-20 4:32 pm | Edgewise Therapeutics Inc. | EWTX | Thompson Peter A. Director 10% Owner | 138,000 | $7.21 | $994,980 | 13,817,055 (Indirect) | View |
2022-05-16 Sale | 2022-05-18 5:15 pm | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 10,800 | $7.4209 | $80,146 | 3,000 (Direct) | View |
2021-11-15 Sale | 2021-11-17 6:05 pm | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 479 | $19.11 | $9,155 | 0 (Direct) | View |
2021-11-09 Sale | 2021-11-12 5:24 pm | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 69,740 | $19.91 | $1,388,788 | 479 (Direct) | View |
2021-11-04 Sale | 2021-11-08 7:11 pm | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 29,451 | $19.82 | $583,823 | 70,219 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2022-12-30 Option Award | 2023-01-03 4:44 pm | N/A 2032-12-30 | Edgewise Therapeutics Inc. | EWTX | Semigran Marc Chief Development Officer | 300,000 | $0 | 300,000 (Direct) | View |
2022-10-03 Exercise | 2022-10-05 4:42 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $1.93 | 125,997 (Direct) | View |
2022-10-03 Exercise | 2022-10-05 4:42 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $0 | 125,997 (Direct) | View |
2022-09-06 Exercise | 2022-09-08 4:16 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $1.93 | 130,727 (Direct) | View |
2022-09-06 Exercise | 2022-09-08 4:16 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $0 | 130,727 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:43 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 200,000 | $0 | 200,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:42 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 220,000 | $0 | 220,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:42 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 200,000 | $0 | 200,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:42 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 200,000 | $0 | 200,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:41 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 240,000 | $0 | 240,000 (Direct) | View |
2022-08-08 Option Award | 2022-08-10 5:41 pm | N/A 2032-08-08 | Edgewise Therapeutics Inc. | EWTX | KOCH KEVIN President and CEO | 550,000 | $0 | 550,000 (Direct) | View |
2022-08-03 Exercise | 2022-08-05 4:12 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $1.93 | 248,015 (Direct) | View |
2022-08-03 Exercise | 2022-08-05 4:12 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 9,232 | $0 | 248,015 (Direct) | View |
2022-08-03 Exercise | 2022-08-05 4:12 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,502 | $0.71 | 248,015 (Direct) | View |
2022-07-05 Exercise | 2022-07-07 4:23 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,730 | $1.93 | 395,480 (Direct) | View |
2022-07-05 Exercise | 2022-07-07 4:23 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 9,232 | $0 | 395,480 (Direct) | View |
2022-07-05 Exercise | 2022-07-07 4:23 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 4,502 | $0.71 | 395,480 (Direct) | View |
2022-06-24 Option Award | 2022-06-28 7:17 pm | 2023-06-08 2032-06-24 | Edgewise Therapeutics Inc. | EWTX | Thompson Peter A. Director 10% Owner | 42,087 | $0 | 42,087 (Direct) | View |
2022-06-24 Option Award | 2022-06-28 7:16 pm | 2023-06-08 2032-06-24 | Edgewise Therapeutics Inc. | EWTX | ROOT JONATHAN D Director | 42,087 | $0 | 42,087 (Direct) | View |
2022-06-24 Option Award | 2022-06-28 7:16 pm | 2023-06-08 2032-06-24 | Edgewise Therapeutics Inc. | EWTX | Edris Badreddin Director | 42,087 | $0 | 42,087 (Direct) | View |
2022-06-24 Option Award | 2022-06-28 7:16 pm | 2023-06-08 2032-06-24 | Edgewise Therapeutics Inc. | EWTX | Brege Laura Director | 42,087 | $0 | 42,087 (Direct) | View |
2022-06-16 Exercise | 2022-06-21 6:50 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 54,419 | $1.93 | 607,580 (Direct) | View |
2022-06-16 Exercise | 2022-06-21 6:50 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 67,927 | $0 | 607,580 (Direct) | View |
2022-06-16 Exercise | 2022-06-21 6:50 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 13,508 | $0.71 | 607,580 (Direct) | View |
2022-06-13 Exercise | 2022-06-15 6:39 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 585 | $1.93 | 644,324 (Direct) | View |
2022-06-13 Exercise | 2022-06-15 6:39 pm | N/A 2030-09-01 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 26,381 | $0 | 644,324 (Direct) | View |
2022-06-13 Exercise | 2022-06-15 6:39 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 25,796 | $0.71 | 644,324 (Direct) | View |
2022-06-08 Exercise | 2022-06-10 6:34 pm | N/A 2030-09-01 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 27,306 | $0 | 507,463 (Direct) | View |
2022-06-08 Exercise | 2022-06-10 6:34 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 27,306 | $0.71 | 507,463 (Direct) | View |
2022-06-03 Exercise | 2022-06-07 7:03 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 30,137 | $1.93 | 797,815 (Direct) | View |
2022-06-03 Exercise | 2022-06-07 7:03 pm | N/A 2030-12-15 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 47,287 | $0 | 797,815 (Direct) | View |
2022-06-03 Exercise | 2022-06-07 7:03 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 17,150 | $0.71 | 797,815 (Direct) | View |
2022-05-23 Exercise | 2022-05-25 6:11 pm | N/A 2030-09-01 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 9,000 | $0.71 | 219,122 (Direct) | View |
2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | Carruthers R Michael Chief Financial Officer | 15,625 | $0 | 15,625 (Direct) | View |
2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | Derakhshan Behrad Chief Business Officer | 15,625 | $0 | 15,625 (Direct) | View |
2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 15,625 | $0 | 15,625 (Direct) | View |
2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 15,625 | $0 | 15,625 (Direct) | View |
2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | Donovan Joanne M. CMO | 31,250 | $0 | 31,250 (Direct) | View |
2022-05-01 Option Award | 2022-05-03 4:14 pm | N/A 2025-05-01 | Edgewise Therapeutics Inc. | EWTX | KOCH KEVIN President and CEO | 31,250 | $0 | 31,250 (Direct) | View |
2022-02-25 Other | 2022-02-28 8:04 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | ROOT JONATHAN D Director | 3,473,543 | $0 | 3,489,168 (Indirect) | View |
2022-01-21 Exercise | 2022-01-25 6:50 pm | N/A 2030-09-01 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 5,400 | $0 | 217,684 (Direct) | View |
2022-01-21 Exercise | 2022-01-25 6:50 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 5,400 | $0.71 | 217,684 (Direct) | View |
2021-12-28 Exercise | 2021-12-30 5:51 pm | N/A 2030-09-01 | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 5,400 | $0 | 217,684 (Direct) | View |
2021-12-28 Exercise | 2021-12-30 5:51 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | MOORE JOHN R General Counsel | 5,400 | $0.71 | 217,684 (Direct) | View |
2021-11-30 Exercise | 2021-12-01 6:20 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 147,585 | $0.18 | 302,937 (Direct) | View |
2021-11-30 Exercise | 2021-12-01 6:20 pm | N/A 2027-08-08 | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 172,585 | $0 | 302,937 (Direct) | View |
2021-11-30 Exercise | 2021-12-01 6:20 pm | N/A N/A | Edgewise Therapeutics Inc. | EWTX | Russell Alan J Chief Scientific Officer | 25,000 | $0.45 | 302,937 (Direct) | View |